| 产品详情 |
| Edit |   |
|---|
| Product Name | Histone Lysine Demethylase Inhibitor VIII, GSK-J4 |
|---|
| Description | Purity ~98% (HPLC). A cell-permeable GSK-J1 prodrug that is ineffective in cell-free assays, but is effectively converted to GSK-J1 intracellularly for effective JMJD3 and UTX inhibition (effective conc. 25 to 50uM in HeLa cultures). GSK-J4 treatment is shown to block LPS-induced TNF-alpha production in primary human macrophage cultures (IC50 = 9uM by ELISA). Primary Target: H3K27me3 demethylases JMJD3 & UTX Molar Mass: 417.5 Solubility: DMSO |
|---|
| Size | 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Histone Lysine Demethylase Inhibitor VIII, GSK-J4 (Ethyl-3-(6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-ylamino)propanoate, GSK-J1 Pro-Drug, JHDM Inhibitor II Pro-Drug) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217431 |
|---|
| Price | |
|---|
| Order / More Info | Histone Lysine Demethylase Inhibitor VIII, GSK-J4 from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|